Expression of carboxyl terminus of Hsp70‑interacting protein (CHIP) indicates poor prognosis in human gallbladder carcinoma

Liang,Zhe  Long; Kim,Meeran; Huang,Song  Mei; Lee,Hyo  Jin; Kim,Jin‑Man

doi:10.3892/ol.2013.1138

Expression of carboxyl terminus of Hsp70‑interacting protein (CHIP) indicates poor prognosis in human gallbladder carcinoma

Authors:
- Zhe Long Liang
- Meeran Kim
- Song Mei Huang
- Hyo Jin Lee
- Jin‑Man Kim
View Affiliations

Affiliations: Department of Pathology, Chungnam National University School of Medicine, Jung‑Gu, Daejeon 301‑131, Republic of Korea, Department of Internal Medicine, Chungnam National University School of Medicine, Jung‑Gu, Daejeon 301‑131, Republic of Korea
Published online on: January 15, 2013 https://doi.org/10.3892/ol.2013.1138
Pages: 813-818

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gallbladder carcinoma (GBC) is a lethal neoplasm, and new prognostic markers are required. Deregulation of E3 ligases contributes to cancer development and is associated with poor prognosis. Carboxyl terminus of heat shock protein 70‑interacting protein (CHIP) is a U‑box‑type E3 ubiquitin ligase, the role of which has not been evaluated in GBC. Therefore, the present study investigated CHIP expression in GBC and its prognostic significance. In the present study, CHIP expression was measured in 78 tumor specimens of GBC by immunohistochemistry and the correlation between CHIP expression and clinicopathological factors was analyzed. Of the tumor specimens, 26.9% showed high staining intensity [the CHIP high expression group (HEG)]. The CHIP‑HEG was not associated with other common clinicopathological parameters, including T stage, and lymph node and distant metastases. CHIP‑HEG patients had a significantly worse prognosis than patients with low CHIP expression with median cancer‑specific survival times of 8.0 months (range, 1‑34 months) and 13.0 months (range, 1‑110 months), respectively (P=0.023). Multivariate analyses showed that CHIP expression was close to being an independent risk factor for predicting patient survival. CHIP expression may be associated with a poor prognosis in GBC. Since CHIP is not associated with other clinicopathological prognostic factors, it may serve as an ideal molecular marker for predicting patient outcomes.

View Figures

View References

1	Diehl AK: Epidemiology of gallbladder cancer: a synthesis of recent data. J Natl Cancer Inst. 65:1209–1214. 1980.PubMed/NCBI
2	Randi G, Franceschi S and La Vecchia C: Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 118:1591–1602. 2006. View Article : Google Scholar : PubMed/NCBI
3	Miller G and Jarnagin WR: Gallbladder carcinoma. Euro J Surg Oncol. 34:306–312. 2008. View Article : Google Scholar
4	Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J Surg. 196:252–264. 2008. View Article : Google Scholar
5	Balachandran P, Agarwal S, Krishnani N, et al: Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg. 10:848–854. 2006. View Article : Google Scholar : PubMed/NCBI
6	Varga M, Obrist P, Schneeberger S, et al: Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res. 10:3131–3136. 2004. View Article : Google Scholar : PubMed/NCBI
7	Park JS, Yoon DS, Kim KS, et al: Analysis of prognostic factors after curative resection for gallbladder carcinoma. Korean J Gastroenterol. 48:32–36. 2006.(In Korean).
8	Malka D, Boige V, Dromain C, Debaere T, Pocard M and Ducreux M: Biliary tract neoplasms: update 2003. Curr Opin Oncol. 16:364–371. 2004. View Article : Google Scholar : PubMed/NCBI
9	Roa I, de Aretxabala X, Araya JC, et al: Morphological prognostic elements in gallbladder cancer. Rev Med Chil. 130:387–395. 2002.(In Spanish).
10	Roa I, Melo A, Roa J, Araya J, Villaseca M and de Aretxabala X: P53 gene mutation in gallbladder cancer. Rev Med Chil. 128:251–258. 2000.(In Spanish).
11	Itoi T, Watanabe H, Ajioka Y, et al: APC, K ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall bladder suggest two genetic pathways in gall bladder carcinogenesis. Pathol Int. 46:333–340. 1996. View Article : Google Scholar : PubMed/NCBI
12	Puhalla H, Wrba F, Kandioler D, et al: Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gall-bladder cancer. Anticancer Res. 27:1679–1684. 2007.PubMed/NCBI
13	Shi YZ, Hui AM, Li X, Takayama T and Makuuchi M: Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gall-bladder carcinomas. Clin Cancer Res. 6:4096–4100. 2000.PubMed/NCBI
14	Zhi YH, Liu RS, Song MM, et al: Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol. 11:3724–3728. 2005. View Article : Google Scholar : PubMed/NCBI
15	Giatromanolaki A, Sivridis E, Simopoulos C, et al: Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol. 94:242–247. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kim YW, Huh SH, Park YK, Yoon TY, Lee SM and Hong SH: Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep. 8:1127–1132. 2001.PubMed/NCBI
17	Zhang M, Pan JW, Ren TR, Zhu YF, Han YJ and Kühnel W: Correlated expression of inducible nitric oxide synthase and P53, Bax in benign and malignant diseased gallbladder. Ann Anat. 185:549–554. 2003. View Article : Google Scholar : PubMed/NCBI
18	Roa I, Ibacache G, Melo A, et al: Subserous gallbladder carcinoma: expression of cadherine-catenine complex. Rev Med Chil. 130:1349–1357. 2002.(In Spanish).
19	Chang HJ, Jee CD and Kim WH: Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am J Surg Pathol. 26:758–766. 2002. View Article : Google Scholar : PubMed/NCBI
20	Choi YL, Xuan YH, Shin YK, et al: An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions. J Histochem Cytochem. 52:591–601. 2004. View Article : Google Scholar : PubMed/NCBI
21	Choi SY, Jo YS, Huang SM, et al: L1 cell adhesion molecule as a novel independent poor prognostic factor in gallbladder carcinoma. Hum Pathol. 42:1476–1483. 2011. View Article : Google Scholar : PubMed/NCBI
22	Connell P, Ballinger CA, Jiang J, et al: The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol. 3:93–96. 2001. View Article : Google Scholar : PubMed/NCBI
23	Demand J, Alberti S, Patterson C and Höhfeld J: Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol. 11:1569–1577. 2001. View Article : Google Scholar : PubMed/NCBI
24	Zhou P, Fernandes N, Dodge IL, et al: ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem. 278:13829–13837. 2003. View Article : Google Scholar : PubMed/NCBI
25	Luo W, Zhong J, Chang R, Hu H, Pandey A and Semenza GL: Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1α but not HIF-2α. J Biol Chem. 285:3651–3663. 2010.PubMed/NCBI
26	Jang KW, Lee JE, Kim SY, et al: The C-terminus of Hsp70-interacting protein promotes Met receptor degradation. J Thorac Oncol. 6:679–687. 2011. View Article : Google Scholar : PubMed/NCBI
27	Esser C, Scheffner M and Höhfeld J: The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem. 280:27443–27448. 2005. View Article : Google Scholar : PubMed/NCBI
28	Tripathi V, Ali A, Bhat R and Pati U: CHIP chaperones wild type p53 tumor suppressor protein. J Biol Chem. 282:28441–28454. 2007. View Article : Google Scholar : PubMed/NCBI
29	McDonough H, Charles PC, Hilliard EG, et al: Stress-dependent Daxx-CHIP interaction suppresses the p53 apoptotic program. J Biol Chem. 284:20649–20659. 2009. View Article : Google Scholar : PubMed/NCBI
30	Gao Y, Han C, Huang H, et al: Heat shock protein 70 together with its co-chaperone CHIP inhibits TNF-alpha induced apoptosis by promoting proteasomal degradation of apoptosis signal-regulating kinase1. Apoptosis. 15:822–833. 2010. View Article : Google Scholar : PubMed/NCBI
31	Li F, Xie P, Fan Y, et al: C terminus of Hsc70-interacting protein promotes smooth muscle cell proliferation and survival through ubiquitin-mediated degradation of FoxO1. J Biol Chem. 284:20090–20098. 2009. View Article : Google Scholar : PubMed/NCBI
32	Xu T, Zhou Q, Zhou J, et al: Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci. 102:959–966. 2011. View Article : Google Scholar : PubMed/NCBI
33	Salvesen GS and Duckett CS: IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 3:401–410. 2002.
34	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI
35	Duan L, Miura Y, Dimri M, et al: Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem. 278:28950–28960. 2003. View Article : Google Scholar : PubMed/NCBI
36	Harper JW, Burton JL and Solomon MJ: The anaphase-promoting complex: it’s not just for mitosis any more. Genes Dev. 16:2179–2206. 2002.
37	Li SH, Li CF, Sung MT, et al: Skp2 is an independent prognosticator of gallbladder carcinoma among p27Kip1-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray. Mod Pathol. 20:497–507. 2007. View Article : Google Scholar : PubMed/NCBI
38	Lakshmanan M, Bughani U, Duraisamy S, Diwan M, Dastidar S and Ray A: Molecular targeting of E3 ligases - a therapeutic approach for cancer. Expert Opin Ther Targets. 12:855–870. 2008. View Article : Google Scholar : PubMed/NCBI
39	Sun Y: E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia. 8:645–654. 2006. View Article : Google Scholar : PubMed/NCBI
40	Kajiro M, Hirota R, Nakajima Y, et al: The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol. 11:312–319. 2009. View Article : Google Scholar : PubMed/NCBI